Search results
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks· 11 hours agoFree Report) reported a loss of 69 cents per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 73 cents. In the year-ago quarter, Kymera reported a ...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 2 days agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
Repertoire pivot pays dividends with Bristol Myers deal
BioPharma Dive via Yahoo Finance· 4 days agoThe alliance validates the new direction pursued by Repertoire, a startup that cut staff and...
Tapinarof Cream for Adult, Pediatric Eczema Under FDA Review
Medscape· 3 days agoA decision on approval is expected in the fourth quarter of 2024.
AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That
Investor's Business Daily· 7 days agoEarnings per share fell 6.1% but topped forecasts by a nickel, according to FactSet. Earnings took...
JNJ- A Healthcare Giant That's Looking More Attractive by the Day
MoneyShow via Yahoo Finance· 1 day agoOwning is good, but I don’t want to own a perception or illusion. What we practice and preach is owning shares of high-quality companies that we have torn apart and looked at under the hood ...
The Expert's Guide to Using Oils for Hair Growth
InStyle via Yahoo News· 4 days agoThe ultimate guide to hair oils for hair growth, including their exact benefits, how to use them, and the products the pros swear by for long, lush...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 1 day agoBMS strengthened its neuroscience portfolio with the acquisition of Karuna Therapeutics, and its lead asset, KarXT (trospium chloride + xanomeline), a...
Change Eligibility Rules for More Diverse Clinical Trials?
Medscape· 11 hours agoExpanding eligibility criteria is a strategy for improving the inclusion of traditionally...
AbbVie Is 'Firing On All Cylinders,' But Its Stock Isn't
Investor's Business Daily· 7 days agoShares tumbled despite a first-quarter beat and earnings guidance increase.